A Podful of Pediatrics

The One Where We Talk About RSV

Episode Summary

RSV (Respiratory Syncytial Virus) is the leading cause of serious lung infections and hospitalizations in babies under 1 year old. In this video, we explain how RSV causes bronchiolitis—swelling, mucus, and inflammation in tiny airways—that leads to coughing, wheezing, and breathing difficulties. Learn why nearly every child gets RSV by age 2, how it spreads, and why feeding can be tough when babies struggle to breathe. We’ll also cover the latest prevention options, including monoclonal antibodies like Synagis and the new Beyfortus shot—what they are, who should get them, and how they protect babies during RSV season. If you’re a parent or caregiver, this video is your go-to guide for understanding RSV symptoms, risks, and prevention.

Episode Notes

1. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390:946.

2. Patton ME, Moline HL, Whitaker M, et al. Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep 2025; 74:273.

3. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:920.

4. Muller WJ, Madhi SA, Seoane Nuñez B, et al. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med 2023; 388:1533.

5. Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol 2022; 40:1722.

6. Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. 2001